Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase EARLY_PHASE1 1Phase 3 1

Status

Recruiting 21Completed 4Terminated 2Active not recruiting 2Withdrawn 1Not yet recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 4

Conditions

Breast Neoplasms 3Advanced ER+, HER2-Negative Breast Cancer 1

Interventions

Cyclophosphamide 1488Cisplatin 1410Paclitaxel 1316Radiotherapy 1259Carboplatin 1247Gemcitabine 1214Docetaxel 1110Bevacizumab 1029Fluorouracil 894Doxorubicin 786Dexamethasone 746Rituximab 719Capecitabine 716Oxaliplatin 700pembrolizumab 673Etoposide 673Irinotecan 634Filgrastim 621Cytarabine 584Leucovorin 578Nivolumab 557Vincristine 510Prednisone 474Cetuximab 464Bortezomib 457Erlotinib Hydrochloride 456Trastuzumab 448Methotrexate 437Lenalidomide 426Pemetrexed 419

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × Interventional × elacestrant × Clear all
NCT03778931 2025-09-15

EMERALD

Stemline Therapeutics, Inc.

Phase 3 Completed
478 enrolled 16 charts 1 FDA
Breast

Breast Neoplasms

NCT04797728 2022-10-26

ELIPSE

SOLTI Breast Cancer Research Group

Phase EARLY_PHASE1 Completed
23 enrolled
Breast

Breast Neoplasms

NCT02338349 2022-08-18

A Phase I, Multicenter, Open-Label, Multi-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer

Stemline Therapeutics, Inc.

Phase 1 Completed
57 enrolled
Breast

Advanced ER+, HER2-Negative Breast Cancer

NCT02650817 2022-08-18

Phase IB Study to Evaluate RAD1901 on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast Cancer

Stemline Therapeutics, Inc.

Phase 1 Completed
16 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡